Trinity Biotech (TRIB) Announces Additional Funding
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology
February 28, 2025 8:30 AM ESTDUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors.
The additional liquidity will support both the continued development of Trinity Biotechs innovative continuous glucose monitoring (CGM) technology and the Companys comprehensive transformation plan. The Company continues to focus much of its growth efforts around its CGM technology, especially given the previously announced positive results from its most recent pre-pivotal... More
